NanoBio Corporation receives U.S. patent for nanoemulsion technology

NanoBio Corporation announced today that it has been awarded a seventh U.S. patent covering its novel nanoemulsion technology. The new claims encompass methods of treating Herpes Simplex I infections, including herpes labialis (commonly referred to as cold sores), using NanoBio's proprietary anti-infective nanoemulsion product candidates.

“The issuance of this patent further demonstrates the novelty of NanoBio's nanoemulsion platform for use in treating dermatological conditions”

This new patent covers NanoBio's NB-001, a novel topical therapy for the treatment of cold sores that has been licensed to GlaxoSmithKline plc (GSK) in the United States and Canada for over-the-counter (OTC) use. NanoBio and GSK are currently preparing to initiate two Phase 3 clinical trials to confirm the efficacy and safety of 0.3% NB-001 and are targeted to launch the product in 2013 - 2014.

"The issuance of this patent further demonstrates the novelty of NanoBio's nanoemulsion platform for use in treating dermatological conditions," said James R. Baker, Jr., MD, chief executive officer and founder of NanoBio. "Given the remarkable safety profile of NB-001 and the clear efficacy demonstrated in our prior clinical trials, we expect NB-001 will make a meaningful contribution to the well being of the millions of people who suffer from cold sores."

The development of the nanoemulsion platform began in the 1990s at the University of Michigan, and has since been supported by over $110 million in grants, investments and partnership funding. The newly issued patent (U.S. #7,767,216) is licensed from the University of Michigan to NanoBio Corp. on an exclusive, worldwide basis. With this new patent, NanoBio now holds seven U.S. patents and has filed over 30 additional U.S. and International applications.